Interleukins as markers of inflammation in malignant and benign thyroid disease

Inflammation Research

Volumn 63, Issue 8, 2014, Pages 667-674

  Provatopoulou, Xeni ^a   Georgiadou, Despoina ^b   Sergentanis, Theodoros N ^a   Kalogera, Eleni ^a   Spyridakis, John ^b   Gounaris, Antonia ^a   Zografos, George N ^b  

^a Hellenic Anticancer Institute   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Inflammation; Interleukins; Serum profiles; Thyroid cancer; Thyroid disorders

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE;

ADULT; BLOOD; FEMALE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; THYROID DISEASE;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION; INTERLEUKINS; MALE; MIDDLE AGED; THYROID DISEASES;

EID: 84904395749     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-014-0739-z     Document Type: Article

References (53)

1. Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Vol. IX. Lyon: IARC Scientific Publication No. 160; 2007.
2. SEER Stat Fact Sheets. Cancer of The Thyroid. 2013. http://seer.cancer. gov/statfacts/html/thyro.html. Accessed 13 Sep 2013.
3. American Thyroid Association. Thyroid Nodules. 2012. http://www.thyroid. org/wp-content/uploads/patients/brochures/Nodules-brochure.pdf. Accessed 13 Sep 2013.
4. Hegedüs L. Clinical Practice. The thyroid nodule. N Engl J Med. 2004;351:1764-71.
5. Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem. 2010;17:3449-61.
6. Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and inflammation. Mol Cell Endocrinol. 2010;321:94-102.
7. Russell JP, Shinohara S, Melillo RM, Castellone MD, Santoro M, Rothstein JL. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene. 2003;22:4569-77. (Pubitemid 36920700)
8. Iwahashi N, Murakami H, Nimura Y, Takahashi M. Activation of RET tyrosine kinase regulates interleukin-8 production by multiple signalling pathways. Biochem Biophys Res Commun. 2002;294:642-9. (Pubitemid 34694059)
9. Russell JP, Engiles JB, Rothstein JL. Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J Immunol. 2004;172:4059-67. (Pubitemid 38375217)
10. Shinohara S, Rothstein JL. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. Oncogene. 2004;23:7571-9. (Pubitemid 39389698)
11. Puxeddu E, Knauf JA, Sartor MA, et al. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer. 2005;12:319-34. (Pubitemid 40896450)
12. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signalling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005;115:1068-81. (Pubitemid 40489412)
13. Borello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. PNAS. 2005;102:14825-30. (Pubitemid 41457140)
14. Castellone MD, Celetti A, Guarino V, et al. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene. 2004;23:2188-96. (Pubitemid 38482533)
15. Ameri P, Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what's new? Neuroendocrinology. 2012;95:267-76.
16. Barzon L, Bonaguro R, Castagliuolo I, et al. Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and Herpes Simplex Virus thymidine kinase. Eur J Endocrinol. 2003;148:73-80. (Pubitemid 36176007)
17. Vitale G, Lupoli G, Guarrasi R, et al. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2013;98:E1567-74.
18. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol. 2002;160:2157-67. (Pubitemid 34663407)
19. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 2003;195:168-86. (Pubitemid 36384291)
20. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol. 2003;120:71-7. (Pubitemid 37046372)
21. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metabol. 2003;88:5399-404. (Pubitemid 37452745)
22. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-7. (Pubitemid 36373628)
23. Xu X, Quiros RM, Gattuso P, Ain KB, Peinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-7. (Pubitemid 36951030)
24. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-80. (Pubitemid 36920701)
25. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Nat Cancer Inst. 2003;95:625-7. (Pubitemid 36553510)
26. Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope. 1997;107:95-100. (Pubitemid 27045201)
27. Sheils OM, O'eary JJ, Uhlmann V, Lättich K, Sweeney EC. RET/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol. 2000;8:185-9.
28. Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and non irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metabol. 2001;86:3211-6. (Pubitemid 32673490)
29. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer. 2002;2:543-9. (Pubitemid 37328936)
30. Pisanu A, Piu S, Cois A, Uccheddu A. Coexisting Hashimoto's thyroiditis with differentiated thyroid cancer and benign thyroid disease: indications for thyroidectomy. Chir Ital. 2003;55:365-72.
31. Khatami M. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity. Cell Biochem Biophys. 2009;55:55-79.
32. Ahn D, Heo SJ, Park JH, et al. Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol. 2011;50:1228-34.
33. Huang BY, Hseuh C, Chao TC, Lin KJ, Lin JD. Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol. 2011;22:144-9.
34. Lun Y, Wu X, Xia Q, et al. Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013;148:396-402.
35. Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab. 2013;98:2409-14.
36. Linkov F, Ferris RL, Yurkovetsky Z, et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin Appl. 2008;2:1575-85.
37. Perkins NJ, Schisterman EF. The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163:670-5.
38. Veselý D, Astl J, Lastůvka P, Matucha P, Sterzl I, Betka J. Serum levels of IGF-I, HGF, TGFbeta1, bFGF and VEGF in thyroid gland tumors. Physiol Res. 2004;53:83-9. (Pubitemid 38295545)
39. Ling MM, Ricks C, Lea P. Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn. 2007;7:87-98. (Pubitemid 46114709)
40. Breen EC, Reynolds SM, Cox C, et al. Multisite comparison of high-sensitivity multiplex assays. Clin Vaccine Immunol. 2011;18:1229-42.
41. Kobawala TP, Patel GH, Gajjar DR, et al. Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases. J Thyroid Res. 2011;. doi:10.4061/2011/270149.
42. Zhao ZF, Wei Q, Zhao Y, et al. Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules. Endocrine. 2009;36:155-60.
43. Ozgen AG, Karadeniz M, Erdogan M, et al. The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Inv. 2009;32:491-4.
44. Erdogan M, Karadeniz M, Ozbek M, Ozgen AG, Berdeli A. Interleukin-10 gene polymorphisms in patients with papillary thyroid cancer in Turkish population. J Endocrinol Inv. 2008;31:750-4.
45. Basolo F, Fiore L, Pollina L, Fontanini G, Conaldi PG, Toniolo A. Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies. Clin Cancer Res. 1998;4:381-7. (Pubitemid 28122753)
46. Ruggeri RM, Villary D, Simone A, et al. Co-expression of interleukin-6 (IL-6) and inteleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor. J Endocrinol Inv. 2002;25:959-66. (Pubitemid 36113280)
47. Muzza M, Degl'Innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol. 2010;72:702-8.
48. Fujarewicz K, Jarzab M, Eszlinger M, et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Rel Cancer. 2007;14:809-26. (Pubitemid 350074069)
49. Bossowski A, Urban M. Serum levels of cytokines in children nd adolescents with Graves' disease and non-toxic nodular goiter. J Pediatr Endocrinol Metab. 2011;14:741-7.
50. Senturk T, Kozaci LD, Kok F, Kadikoylu G, Bolaman Z. Pro-inflammatory cytokine levels in hyperthyroidism. Clin Invest Med. 2003;26:58-63.
51. Domberg J, Liu C, Paperwalis C, et al. Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res. 2008;40:416-21. (Pubitemid 351967134)
52. Gu LQ, Jia HY, Zhao YJ, et al. Association studies of interleukin-8 gene in Graves' disease and Graves' ophthalmopathy. Endocrine. 2009;36:452-6.
53. Inoue N, Watanabe M, Morita M, et al. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol. 2011;163:318-23.